---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-119898"
form_type: "8-K"
ticker: "ONCO"
cik: "0001782107"
company_name: "Onconetix, Inc."
filed_at: "2025-12-10T23:59:59+00:00"
generated_at: "2026-05-16T13:39:24.753933+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Onconetix subsidiary amends Labcorp license; up to $300k for PRIME study of Proclarix

## Summary
- Proteomedix (wholly owned by Onconetix) amended license with Labcorp for a new validation study of Proclarix (PRIME Study).
- Onconetix will pay Labcorp milestone-based payments up to $300,000 total and bear all study costs.
- Mid-five-figure payments per enrolled subject batch; fixed per-subject fee if final milestone not met.
- Labcorp not required to pay royalties or milestones for use of the risk calculator in this PRIME Study.
- Labcorp must provide study results to Onconetix but Onconetix cannot use or disclose without Labcorp's consent.

## SEC filing metadata
- accession: 0001213900-25-119898
- form_type: 8-K
- ticker: ONCO
- cik: 0001782107
- company_name: Onconetix, Inc.
- filed_at: 2025-12-10T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1782107/000121390025119898/0001213900-25-119898-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1782107/000121390025119898/ea0269052-8k_onconetix.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-119898
- JSON: https://secwatch.observer/filing/0001213900-25-119898.json
- Plain text: https://secwatch.observer/filing/0001213900-25-119898.txt

## Key facts
- Material Agreements
  Onconetix, Inc. amended Amendment with Laboratory Corporation of America Holdings (Labcorp) (effective 2025-12-06).
  - Action: amendment
  - Agreement: license
  - Counterparty: Laboratory Corporation of America Holdings (Labcorp)
  - Effective: 2025-12-06
  source text: On December 6, 2025, Proteomedix AG, a Swiss Company (“Proteomedix”), a wholly-owned subsiairy of Onconetix, Inc. (the “Company”), entered into an amendment (the “Amendment”) of the license agreement with Laboratory Corporation of America Holdings (“Labcorp”) dated as of March 27, 2023, by and between the Company and Labcorp (the “Agreement”), pursuant to which Labcorp has the exclusive right to develop and commercialize Proclarix and other products developed by Labcorp using Proteomedix’s intellectual property covered by the license in the United States (the “Licensed Products”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1782107/000121390025119898/0001213900-25-119898-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.